AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
On July 14, 2026, Celcuity Inc., a clinical-stage biopharmaceutical company based in Minneapolis and listed on NASDAQ under the ticker CELC, announced that the U.S. Food and Drug Administration has granted approval for REVTORPYK™ (gedatolisib) to treat a specific subset of hormone receptor positive, HER2-negative metastatic breast cancer patients who lack a PIK3CA mutation and have progressed following at least one line of endocrine therapy. This approval addresses a previously underserved patient group with limited targeted treatment options. Celcuity expects to commercially launch REVTORPYK in late Q3 2026 and plans to submit a supplemental New Drug Application (sNDA) for an additional breast cancer indication. This milestone marks Celcuity's transition from a development-stage to a commercial-stage company, significantly impacting its operational and financial profile.
Key Points
- NASDAQ: CELC
- FDA approved REVTORPYK™ (gedatolisib) on July 14, 2026, for HR+/HER2- locally advanced or metastatic breast cancer patients without a PIK3CA mutation who progressed after at least one endocrine therapy line in the metastatic setting.
- Celcuity aims for a commercial launch of REVTORPYK in late Q3 2026 and plans to submit a supplemental NDA for PIK3CA-mutated breast cancer indication in Q3 2026, based on Phase 3 VIKTORIA-1 trial data.
- Investors will monitor updates on the commercial launch timeline, sNDA submission for the PIK3CA-mutated population, and early market uptake following the late Q3 2026 launch.
FDA Approves REVTORPYK for PIK3CA Wild-Type HR+/HER2- Metastatic Breast Cancer
On July 14, 2026, the FDA authorized REVTORPYK™ (gedatolisib) for adult patients with hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer who do not carry a PIK3CA mutation and whose disease has progressed after at least one prior endocrine therapy in the metastatic setting. This approval specifically targets the PIK3CA wild-type patient group, historically challenging due to limited targeted therapy options. Most existing treatments focus on PIK3CA-mutated patients, leaving this population underserved.
Celcuity announced the approval through a press release and hosted a live webcast and conference call at 4:30 p.m. Central Time on the same day to discuss the regulatory outcome and implications. An investor presentation accompanied the announcement, highlighting this pivotal regulatory achievement for gedatolisib, a PI3K/mTOR inhibitor central to Celcuity’s clinical pipeline.
REVTORPYK Commercial Launch Expected in Late Q3 2026
Celcuity revealed plans to commercially launch REVTORPYK in late Q3 2026, indicating readiness with launch infrastructure ahead of FDA approval. The company did not disclose specific launch dates, pricing, distribution strategies, or projected revenues in the announcement. Investors will likely scrutinize the commercial execution as Celcuity shifts from development to marketing, a critical operational phase for the company. Details on launch costs and pre-commercial investments were not provided.
The late Q3 2026 timeline suggests REVTORPYK will be accessible to healthcare providers and patients within weeks of FDA approval.
Supplemental NDA for PIK3CA-Mutated Breast Cancer Submission Planned for Q3 2026
Celcuity plans to submit a supplemental New Drug Application in Q3 2026 to extend REVTORPYK’s indication to HR+/HER2- locally advanced or metastatic breast cancer patients with a PIK3CA mutation who have undergone at least one prior endocrine therapy. This represents a larger patient population and would expand gedatolisib’s market potential upon approval.
The sNDA submission will be supported by data from the mutant cohort of the Phase 3 VIKTORIA-1 trial. While detailed efficacy and safety results were not disclosed, the company indicated the data support regulatory submission. Slide 18 of the investor presentation (Exhibit 99.2) provides additional context on this supplemental application strategy.
Phase 3 VIKTORIA-1 Trial Underpins Both Approved and Planned Indications
The Phase 3 VIKTORIA-1 trial enrolled two cohorts: PIK3CA wild-type patients forming the basis for the current approval, and a mutant cohort supporting the upcoming sNDA. This dual-cohort design enabled Celcuity to pursue regulatory approval for both molecularly defined populations within one pivotal study.
The company noted topline clinical results are based on ongoing efficacy and safety analyses, with data subject to change upon further review. Specific response rates, progression-free survival, or overall survival data were not disclosed in this announcement.
Gedatolisib Targets PI3K/mTOR Pathways in Breast Cancer Treatment
Gedatolisib inhibits PI3K and mTOR signaling pathways, key drivers of tumor growth and survival in hormone receptor positive breast cancer. The distinction between PIK3CA-mutated and wild-type tumors is clinically important, as mutation status influences response to PI3K pathway inhibitors. The FDA approval for the PIK3CA wild-type population is notable, addressing patients for whom prior PI3K-targeted therapies lacked sufficient benefit for approval.
This differentiation positions REVTORPYK uniquely among therapies in this class, although comparative efficacy data versus other approved treatments were not provided.
Approval Announcement Accompanied by Conference Call and Investor Presentation
Celcuity hosted a live webcast and conference call on July 14, 2026, at 4:30 p.m. Central Time to discuss the FDA approval. An investor presentation was filed as Exhibit 99.2, with Slide 18 referenced for supplemental NDA strategy details. This engagement aligns with standard practices for commercial-stage biopharmaceutical companies communicating regulatory milestones and product launches to investors.
The presentation and press release were furnished under Regulation FD, clarifying the information is furnished but not filed for liability purposes under the Securities Exchange Act of 1934. No further content details beyond the sNDA strategy slide were disclosed.
Celcuity’s Corporate Profile and NASDAQ Listing
Celcuity Inc., incorporated in Delaware and headquartered at 2800 Campus Drive, Suite 140, Minneapolis, Minnesota, trades common stock (par value $0.001) on The Nasdaq Stock Market LLC under the ticker CELC. The company is not classified as an emerging growth company under relevant Securities Act and Exchange Act rules. CEO Brian F. Sullivan signed the July 14, 2026 filing.
Focused on developing gedatolisib as its lead asset, Celcuity’s FDA approval for REVTORPYK marks the culmination of its development efforts for the PIK3CA wild-type breast cancer indication. With a commercial launch and supplemental application planned in late Q3 2026, the company enters a phase of increased operational activity. Financial details such as cash position, partnerships, or runway were not disclosed.
Forward-Looking Statements and Risk Factors Highlighted
The announcement included extensive forward-looking statements as required by the Private Securities Litigation Reform Act of 1995. Celcuity identified risks including clinical trial delays, potential non-approval of the sNDA for the PIK3CA-mutated indication, regulatory maintenance challenges, competition, and capital access risks. These are common in the biopharmaceutical industry.
Additional risks are detailed in Celcuity’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings. The company disclaims any obligation to update forward-looking statements post-filing and advises investors not to place undue reliance on them.
Market and Investor Impact of REVTORPYK Approval
The FDA approval of REVTORPYK for the PIK3CA wild-type HR+/HER2- metastatic breast cancer population is a transformative event for Celcuity, enabling the company to generate product revenue for the first time. This transition shifts the company’s financial profile from solely R&D expenditures to include commercial operations. The anticipated late Q3 2026 launch suggests commercialization activity may soon be reflected in financial reports.
At the time of this report, immediate share price effects were unclear. Investors are expected to track the commercial launch progress, sNDA submission updates for the PIK3CA-mutated group, and company guidance on market uptake and resource allocation. The dual-indication approach indicates Celcuity’s strategy to address a broad segment of the HR+/HER2- metastatic breast cancer market across molecular subtypes.
